



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/30 (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE



REQUEST FOR CONTINUED EXAMINATION (RCE) TRANSMITTAL

Address to:
Commissioner for Patents
Box RCE
Washington, DC 20231

Application Number	09/762,602
Filing Date	March 21, 2001
First Named Inventor	Petros Karouzakis
Art Unit	1617
Examiner Name	Hui
Attorney Docket Number	1581/128

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application.
Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

1. Submission required under 37 CFR 1.114

- a. ☐ Previously submitted
- i. ☐ Consider the amendment(s)/reply under 37 CFR 1.116 previously filed on _____
(Any unentered amendment(s) referred to above will be entered).
- ii. ☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on _____
- iii. ☐ Other _____
- b. ☒ Enclosed
- i. ☒ Amendment/Reply
- ii. ☐ Affidavit(s)/Declaration(s)
- iii. ☒ Information Disclosure Statement (IDS)
- iv. ☒ Other Declaration in Support of Applicant's Response

2. Miscellaneous

- a. ☐ Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of _____ months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)
- b. ☐ Other _____

3. Fees

The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.

- a. ☒ The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 19-4972
- i. ☐ RCE fee required under 37 CFR 1.17(e)
- ii. ☐ Extension of time fee (37 CFR 1.136 and 1.17)
- iii. ☐ Other _____
- b. ☒ Check in the amount of \$ 1,140.00 enclosed
- c. ☐ Payment by credit card (Form PTO-2038 enclosed)

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

Name (Print/Type)	Morton Chirnomas	Registration No. (Attorney/Agent)	34,465
Signature		Date	October 15, 2002

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner For Patents, Box RCE, Washington, DC 20231, or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.

Name (Print/Type)	Morton Chirnomas	Date	October 15, 2002
Signature			

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND Fees and Completed Forms to the following address: Assistant Commissioner for Patents, Box RCE, Washington, DC 20231.

RECEIVED

OCT 23 2002

TECH CENTER 1600/2900



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Karouzakis, et al. Atty Dkt: 1581/128
Serial No: 09/762,602 Examiner: Hui,S.
Date Filed: 3/21/01 Group No: 1617
Invention: Use of Misoprostol or/and Date: October 15, 2002
Misoprostol acid for preparing drug in order
to cure sexual dysfunction in women.

#14/c
RND
11/6/02

CERTIFICATE OF MAILING

I hereby certify that this correspondence addressed to the Commissioner for Patents, Washington, D.C. 20231 is being deposited with the United States Postal Service as first class mail on October 15, 2002.

Morton Chirnomas

Commissioner for Patents
Washington, DC 20231

Response ^C

Dear Sir:

In The Claims:

Please amend the claims as follows:

C¹ --30 (Amended). A method according to claim 29, wherein the second agent is alprostadil. --

C² --38 (Amended). A method according to claim 37, wherein the gel contains a polymer
having a concentration of less than 4%. --

C³ --45 (Amended). A pharmaceutical composition according to claim 44, wherein the second
agent is alprostadil.--

Remarks

Claims 27-47 are pending in the present application. In an Office Action mailed May 15, 2002, claims 27-42 were rejected under 35 U.S.C. § 103 in view of Nahoum and Buyuktimkin in view

RECEIVED
OCT 23 2002
TECH CENTER 1600/2900